


02/11/99

JCI35 U.S. PTO  
09/24/97  
66/31/20

<b>UTILITY PATENT APPLICATION TRANSMITTAL</b> <small>for new nonprovisional applications under 37 CFR 1.53(b)</small>	Attorney Docket No.	18-1043-0 DIV
	First Inventor or Application Identifier	HIDENORI OHKI
	Title	CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY

<b>APPLICATION ELEMENTS</b> <small>See MPEP chapter 600 concerning utility patent application contents</small>	<b>ADDRESS TO:</b> Assistant Commissioner for Patents Box Patent Application Washington, DC 20231
<p>1. <input checked="" type="checkbox"/> Fee Transmittal Form (e.g. PTO/SB/17) (Submit an original and a duplicate for fee processing)</p> <p>2. <input checked="" type="checkbox"/> Specification Total Pages <b>270</b></p> <p>3. <input type="checkbox"/> Drawing(s) (35 U.S.C. 113) Total Sheets <b>1</b></p> <p>4. <input checked="" type="checkbox"/> Oath or Declaration Total Pages <b>3</b></p> <p>a. <input type="checkbox"/> Newly executed (original or copy)</p> <p>b. <input checked="" type="checkbox"/> Copy from a prior application (37 C.F.R. §1.63(d)) (for continuation/divisional with box 15 completed)</p> <p>i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §1.63(d)(2) and 1.33(b).</p> <p>5. <input checked="" type="checkbox"/> Incorporation By Reference (usable if box 4B is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4B, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein.</p>	<b>ACCOMPANYING APPLICATION PARTS</b> <p>6. <input type="checkbox"/> Assignment Papers (cover sheet &amp; document(s))</p> <p>7. <input type="checkbox"/> 37 C.F.R. §3.73(b) Statement (when there is an assignee) <input type="checkbox"/> Power of Attorney</p> <p>8. <input type="checkbox"/> English Translation Document (if applicable)</p> <p>9. <input checked="" type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations</p> <p>10. <input type="checkbox"/> Preliminary Amendment</p> <p>11. <input checked="" type="checkbox"/> White Advance Serial No. Postcard</p> <p>12. <input type="checkbox"/> Small Entity Statement(s) <input type="checkbox"/> Statement filed in prior application. Status still proper and desired.</p> <p>13. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed)</p> <p>14. <input checked="" type="checkbox"/> Other: Request for Priority Copy of Form PCT/IB/304</p>
<p>15. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below:</p> <p><input type="checkbox"/> Continuation <input checked="" type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application no.: 08/809,723</p> <p>Prior application information: Examiner: MARSHALL Group Art Unit: 1654</p>	
<p>16. Amend the specification by inserting before the first line the sentence:</p> <p><input checked="" type="checkbox"/> This application is a <input type="checkbox"/> Continuation <input checked="" type="checkbox"/> Division <input type="checkbox"/> Continuation-in-part (CIP) of application Serial No. 08/809,723 Filed on MAY 21, 1997, which was filed as International Application No. PCT/JP/95/01983 on September 29, 1995.</p> <p><input type="checkbox"/> This application claims priority of provisional application Serial No. Filed</p>	
<p><b>17. CORRESPONDENCE ADDRESS</b></p> <p>OBLON, SPIVAK, MCCLELLAND, MAIER &amp; NEUSTADT, P.C. FOURTH FLOOR 1755 JEFFERSON DAVIS HIGHWAY ARLINGTON, VIRGINIA 22202 (703) 413-3000 FACSIMILE: (703) 413-2220</p>	

Name:	Norman F. Oblon	Registration No.:	24,618
Signature:		Date:	2-11-89
Name:	Robert W. Hahl, Ph.D.	Registration No.:	33,893

Docket No. 18-1043-0 DIV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INVENTOR(S) HIDENORI OHKI ET AL

SERIAL NO: New Application

FILING DATE: Herewith

FOR: CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY

FEE TRANSMITTAL


ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

FOR	NUMBER FILED	NUMBER EXTRA	RATE	CALCULATIONS
TOTAL CLAIMS	19 - 20 =	0	× \$18 =	\$0.00
INDEPENDENT CLAIMS	2 - 3 =	0	× \$78 =	\$0.00
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS (If applicable)			+ \$260 =	\$0.00
<input type="checkbox"/> LATE FILING OF DECLARATION			+ \$130 =	\$0.00
BASIC FEE				\$760.00
TOTAL OF ABOVE CALCULATIONS				\$760.00
<input type="checkbox"/> REDUCTION BY 50% FOR FILING BY SMALL ENTITY				\$0.00
<input type="checkbox"/> FILING IN NON-ENGLISH LANGUAGE			+ \$130 =	\$0.00
<input type="checkbox"/> RECORDATION OF ASSIGNMENT			+ \$40 =	\$0.00
TOTAL				\$760.00

- ☐ Please charge Deposit Account No. 15-0030 in the amount of \_\_\_\_\_ A duplicate copy of this sheet is enclosed.
- ☒ A check in the amount of **\$760.00** to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.



Norman F. Oblon

Registration No. 24,618

Robert W. Hahl, Ph.D.

Registration 33,893

Date: 2.11.99

Fourth Floor  
1755 Jefferson Davis Highway  
Arlington, Virginia 22202  
Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 11/98)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: HIDENORI OHKI ET AL

GAU:

SERIAL NO: NEW APPLICATION

EXAMINER:

FILED: HEREWITH

FOR: CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY

REQUEST FOR PRIORITY

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231



SIR:

- ☐ Full benefit of the filing date of U.S. Application Serial Number, filed, is claimed pursuant to the provisions of 35 U.S.C. §120.
- ☐ Full benefit of the filing date of U.S. Provisional Application Serial Number, filed, is claimed pursuant to the provisions of 35 U.S.C. §119(e).
- ☒ Applicants claim any right to priority from any earlier filed applications to which they may be entitled pursuant to the provisions of 35 U.S.C. §119, and/or §120 as noted below.

In the matter of the above-identified application for patent, notice is hereby given that the applicants claim as priority:


<u>COUNTRY</u>	<u>APPLICATION NUMBER</u>	<u>MONTH/DAY/YEAR</u>
GREAT BRITAIN	9420425.2	OCTOBER 07, 1994
GREAT BRITAIN	9508745.8	APRIL 28, 1995
WIPO	PCT/JP95/01983	SEPTEMBER 29, 1995

Certified copies of the corresponding Convention Application(s)

- ☐ are submitted herewith
- ☐ will be submitted prior to payment of the Final Fee
- ☐ were filed in prior application Serial No. filed
- ☒ were submitted to the International Bureau in PCT Application Number PCT/JP95/01983. Receipt of the certified copies by the International Bureau in a timely manner under PCT Rule 17.1(a) has been acknowledged as evidenced by the attached copy of PCT/IB/304.
- ☐ (A) Application Serial No.(s) were filed in prior application Serial No. filed ; and  
(B) Application Serial No.(s)
  - ☐ are submitted herewith
  - ☐ will be submitted prior to payment of the Final Fee

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

  
\_\_\_\_\_  
Norman F. Oblon  
Registration No. 24,618

Robert W. Hahl, Ph.D.  
Registration No. 33,893

Fourth Floor  
1755 Jefferson Davis Highway  
Arlington, Virginia 22202  
Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 11/98)

PCT

NOTIFICATION CONCERNING  
SUBMISSION OF PRIORITY DOCUMENTS

(PCT Administrative Instructions, Section 411)

From the INTERNATIONAL BUREAU

To:

SEKI, Hideo  
Fujisawa Pharmaceutical Co., Ltd.  
Osaka Factory  
1-6, Kashima 2-chome  
Yodogawa-ku, Osaka-shi  
Osaka 532  
JAPON



Date of mailing (day/month/year)

08 November 1995 (08.11.95)

Applicant's or agent's file reference

PWO-14170

## IMPORTANT NOTIFICATION

International application No.

PCT/JP95/01983

International filing date (day/month/year)

29 September 1995 (29.09.95)

Priority date (day/month/year)

07 October 1994 (07.10.94)

Applicant

FUJISAWA PHARMACEUTICAL CO., LTD. et al

The applicant is hereby notified of the date of receipt by the International Bureau of the priority document(s) relating to the following application(s):

Priority application No:

9420425.2

9508745.8

Priority date:

07 Oct 1994 (07.10.94)

28 Apr 1995 (28.04.95)

Priority country:

GB

GB

Date of receipt of priority document:

06 Nov 1995 (06.11.95)

06 Nov 1995 (06.11.95)

The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

N. Kijima

Telephone No.: (41-22) 730.91.11

